Patritumab deruxtecan in patients with EGFR-mutant NSCLC

Pasi Jänne, MD, PhD, Dana-Farber/Harvard Cancer Center, Boston, MA, provides an overview of the Phase I trial (NCT03260491) assessing patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The expansion study included patients with EGFR inhibitor-resistance and there was an overall response rate (ORR) of 39% as well as a median progression-free survival (PFS) of 8.2 months. Prof. Jänne additionally discusses a Phase II trial of patritumab deruxtecan in NSCLC (NCT04619004). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.